Compare GGR & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GGR | IFRX |
|---|---|---|
| Founded | 2011 | 2007 |
| Country | Taiwan | Germany |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.6M | 71.1M |
| IPO Year | N/A | 2017 |
| Metric | GGR | IFRX |
|---|---|---|
| Price | $3.21 | $1.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 21.6K | ★ 658.1K |
| Earning Date | 02-12-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $280,211,000.00 | $73,729.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.15 | $1,054.36 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.72 | $0.71 |
| 52 Week High | $10.15 | $2.77 |
| Indicator | GGR | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 41.98 | 57.33 |
| Support Level | $2.96 | $0.99 |
| Resistance Level | $3.20 | $1.16 |
| Average True Range (ATR) | 0.23 | 0.08 |
| MACD | -0.04 | 0.02 |
| Stochastic Oscillator | 42.72 | 89.13 |
Gogoro Inc is focused on eliminating the barriers to electric fuel adoption to bring swappable electric power within reach of every urban rider. Its battery swapping technology compromises an interoperable platform that seamlessly integrates a comprehensive ecosystem of hardware, software, and services, which consists of Gogoro Smart Batteries, GoStations, Gogoro Network Software & Battery Management Systems, Smartscooter, and related components and kits. Geographical presence in Taiwan and Other countries, majority of its revenue comes from Tiwan.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.